Valneva is a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.
Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO®) and the second (DUKORAL®) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC.
In Austria, Valneva commercialises in addition a typhoid vaccine (Vivotif®) as well as the influenza vaccines Sandovac® and Fluad®.
www.valneva.com resp. www.valneva.at